Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

30th May 2022 07:00

RNS Number : 1653N
Hemogenyx Pharmaceuticals PLC
30 May 2022
 

30 May 2022

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

LEI 2138008L93GYU5GN6179

Director/PDMR Shareholding

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company's issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

2.

Reason for the notification

a)

Position/status

Financial Controller and Company Secretary

b)

Initial notification/amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Full name of the entity

Hemogenyx Pharmaceuticals plc

b)

Legal Entity Identifier code

2138008L93GYU5GN6179

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrumentIdentification code

Ordinary shares of Hemogenyx Pharmaceuticals plcGB00BYX3WZ24

b)

Nature of the transaction

Standalone acquisition of shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP £0.0144

1,284,889

d)

Aggregated information

- Aggregated volume

- Price

Price(s)

Volume(s)

GBP £18,502.40

1,284,889

e)

Date of the transaction

2022-05-27

f)

Place of the transaction

London Stock ExchangeXLON

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Director

[email protected]

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDBGDULBDDGDC

Related Shares:

Hemogenyx
FTSE 100 Latest
Value8,871.31
Change61.57